



**METHODS FOR DIAGNOSING A BIPOLAR DISORDER AND
UNIPOLAR DISORDER**

This application claims the benefit of U.S. Provisional Application No. 60/515,846, filed October 30, 2003, incorporated herein by reference.

5

Field of the Invention

The present invention relates to a method for diagnosing a bipolar disorder. In particular, this method utilizes changes that occur in Na^+K^+ ATPase regulation in cells from bipolar individuals, as compared to cells from unaffected control individuals, to provide a diagnostic assay for a bipolar disorder. The present invention also relates to a method for diagnosing unipolar disorder.

15

Background of the Invention

Mental illness afflicts nearly ten percent of the general population both in the United States and in the rest of the world. Bipolar (manic depressive) disorders occur ~~disorder occurs~~ in one to two percent of the population and are ~~is~~ the sixth leading cause of disability (Coryell et al., *Am. J. Psychiatry* 150:720-727 (1993); Lopez, A.D., and Murray, C.C., *Nat. Med.* 4:1241-1243 (1998); Hyman, S.E., *Am. J. Geriatr. Psychiatry* 9:330-339 (2001)). A problem facing the medical community is misdiagnosis of a bipolar disorder. Misdiagnosed patients receive an average of 3.5 misdiagnoses and consult four physicians before receiving an accurate diagnosis ("Living with bipolar disorder: How far

have we really come?" National Depressive and Manic-Depressive Association, Chicago, IL (2001)).

5 The current diagnostic method for a bipolar disorder (bipolar disorder I and II) involves a series of clinical interviews and examination using the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV), the main diagnostic reference of Mental Health professionals in the United States, which is now in its fourth edition. Significant
10 controversy exists about the validity of this manual, which limits the accuracy of clinical diagnosis (Torrey et al, "Surviving Manic Depression", *Basic Books*, New York (2002)). In addition, attempts are underway to identify the
15 genes underlying these illnesses ~~this illness~~ and thereby develop diagnostic markers. However, their identification and possible use as diagnostic markers are years away (Bradbury, J., *Lancet* 357:1596 (2001)).

20 The lifetime risk for unipolar disorder (major depressive disorder) is 10% to 25% for women and from 5% to 12% for men. At any point in time, 5% to 9% of women and 2% to 3% of men suffer from this disorder. Prevalence is unrelated to ethnicity,
25 education, income, or marital status.

 Like bipolar disorders ~~disorder~~, unipolar disorder is also currently diagnosed using the DSM-IV. By definition, unipolar disorder and bipolar
30 disorders ~~disorder~~ are distinct conditions. Unipolar disorder is diagnosed when there has never been a manic episode and at least five of the following symptoms have been present during the same 2 week depressed period:

- Abnormal depressed mood.
- Abnormal loss of all interest and pleasure.
- Appetite or weight disturbance, either:
 - Abnormal weight loss (when not dieting) or decrease in appetite.
 - Abnormal weight gain or increase in appetite.
- Sleep disturbance, either abnormal insomnia or abnormal hypersomnia.
- Activity disturbance, either abnormal agitation or abnormal slowing (observable by others).
- Abnormal fatigue or loss of energy.
- Abnormal self-reproach or inappropriate guilt.
- Abnormal poor concentration or indecisiveness.
- Abnormal morbid thoughts of death or suicide.

There is evidence that unipolar disorder is, in part, a genetic disorder. Therefore, as with bipolar ~~disorders~~disorder, attempts are underway to identify the genes underlying unipolar disorder and thereby develop diagnostic markers. However, this has yet to be achieved.

In virtually every animal cell, the concentration of Na^+ in the cell (~12 mM) is lower than the concentration of Na^+ in the surrounding medium (~145 mM), and the concentration of K^+ in the cell (~140 mM) is higher than the concentration of K^+ in the surrounding medium (~4 mM). This imbalance is established and maintained by an active transport system in the plasma membrane. The transporter enzyme Na^+K^+ ATPase, also known as the sodium pump, couples breakdown of ATP to the simultaneous movement of both Na^+ and K^+ against their electrochemical gradients. For each molecule of ATP

hydrolyzed to ADP and P_i , the Na^+K^+ ATPase transports two K^+ ions inward and three Na^+ ions outward across the plasma membrane.

5 The Na^+K^+ ATPase is an integral protein with two subunits (M_r ~50,000 and ~110,000), both of which span the membrane. A proposed mechanism by which ATP hydrolysis is coupled to ion transport involves the Na^+K^+ ATPase cycling between two forms, a phosphorylated form with high affinity for K^+ and low
10 affinity for Na^+ , and a dephosphorylated form with high affinity for Na^+ and low affinity for K^+ . The conversion of ATP to ADP and P_i occurs in two steps catalyzed by the enzyme.

In addition to the Na^+K^+ ATPase, the plasma
15 membrane also contains channel proteins that allow the principal cellular ions (Na^+ , K^+ , Ca^{2+} , and Cl^-) to move through them at different rates down their concentration gradients. Ion concentration gradients generated by pumps and selective movement of ions
20 through channels constitutes the principal mechanism by which a difference in voltage, or electric potential, is generated across the plasma membrane. However, because the plasma membranes of animal cells contain many open K^+ channels, and relatively
25 few open Na^+ , Ca^{2+} , and Cl^- channels, the membrane potential in animal cells depends largely on open K^+ channels. As a result, the major ionic movement across the plasma membrane is that of K^+ from the inside outward, powered by the K^+ concentration
30 gradient, leaving an excess of negative charge on the inside and creating an excess of positive charge on the outside.

The magnitude of this membrane potential generally is -50 mV to -70 mV (with the inside of the cell negative relative to the outside), which is characteristic of most animal cells and essential to the conduction of action potentials in neurons. As noted earlier, the K^+ concentration gradient that drives the flow of K^+ ions through open K^+ channels is generated by the Na^+K^+ ATPase. The central role of the Na^+K^+ ATPase is reflected in the energy invested in this reaction: about 25% of the total energy consumption of a human at rest.

The steroid derivative ouabain is a potent and specific inhibitor of the Na^+K^+ ATPase. Ouabain and another steroid derivative, digitoxigenin, are the active ingredients of digitalis, which has long been used to treat congestive heart failure. Inhibition of the Na^+K^+ ATPase by digitalis leads to an increased Na^+ concentration in cells, activating a Na^+Ca^{2+} antiporter in cardiac muscle. The increased influx of Ca^{2+} through this antiporter produces elevated cytosolic Ca^{2+} , which strengthens the contractions of heart muscle.

The Na^+K^+ ATPase has also been investigated for its possible involvement in bipolar disorder pathophysiology (El-Mallakh et al, *Biol. Psychiatry*, 537:235-244 (1995)). However, this has been an unsettled and controversial subject in the field for many years. Na^+K^+ ATPase activity has been variously reported to be increased, decreased, or unchanged in bipolar patients. In 1997, Looney et al conducted a meta-analysis of the available literature on erythrocyte Na^+K^+ ATPase activity in bipolar disorders ~~disorder~~ and concluded that it is lower in

bipolar patients (Looney et al, *Depress. Anxiety*, 5:53-65 (1997)). However, the question of exactly how the Na^+K^+ ATPase plays a role in bipolar disorders ~~disorder~~ remains unanswered.

5 Lithium, an alkaline metal that has been used successfully for over fifty years to stabilize mood in bipolar ~~disorders~~~~disorder~~, has been shown to augment Na^+K^+ ATPase activity. Recently, the role of lithium in depolarizing the resting membrane potential of neurons has been analyzed
10 (Thiruvengadam, *J. Affect. Disord.*, 65:95-99 (2001); and Thiruvengadam, "Electro-biochemical coupling, excitability of neurons and bipolar disorder, *Bipolar Disorder* 3 (2001)). Hyperpolarization of
15 membrane potential in leukocytes of bipolar patients and depolarization following the addition of lithium has been observed (El Mallakh et al, *J. Affect. Disord.*, 41:33-37 (1996)). In addition, a significantly smaller increase in Na^+K^+ ATPase
20 density after incubation for 72 hours in ethacrynate or lithium has been observed in cells of bipolar patients compared to cells of unaffected individuals (Wood et al, *J. Affect. Disord.*, 21:199-206 (1991)).

 El-Mallakh et al measured the transmembrane
25 potential in leukocytes from hospitalized bipolar patients and observed that the transmembrane potential of the bipolar patients was hyperpolarized compared with normal controls and euthymic patients on lithium (El-Mallakh et al, *J. Affect. Disord.*,
30 41:33-37 (1996)). However, ~~Tamella~~~~Buss~~ et al measured the membrane potentials of cultured lymphoblasts and concluded that there was no significant difference in membrane potentials among

bipolar patients, their siblings and normal controls
 | (Buss ~~Tamella~~ et al, *Psychiatry Res.* 59:197-201
 | (1996)).

5 In view of the previously studies on the
 | possible involvement of the Na^+K^+ ATPase in bipolar
 | ~~disorders~~~~disorder~~, one would not expect Na^+K^+ ATPase
 | activity to serve as a reliable basis for diagnosing
 | a bipolar disorder in an individual patient, because
 | measurements of Na^+K^+ ATPase activity are highly
 10 variable. Similarly, one would not expect
 | transmembrane potential to serve as a reliable basis
 | for diagnosing a bipolar disorder in an individual
 | patient, because measurements of transmembrane
 | potential are highly variable.

15 Accordingly, despite the existence of
 | treatments for bipolar ~~disorders~~~~disorder~~ and
 | unipolar disorder and recent advances in the
 | psychiatric field, there remains a heretofore unmet
 | need for clinical tests to augment the DSM-IV in
 20 | diagnosing bipolar ~~disorders~~~~disorder~~ and unipolar
 | disorder.

Summary of the Invention

25 The present invention exploits changes that
 | take place in Na^+K^+ ATPase regulation in cells of
 | bipolar patients, as compared to cells of normal,
 | unaffected control subjects, to provide a diagnostic
 | assay for a bipolar disorder. The present invention
 | provides a reliable diagnostic assay to differentiate
 30 cells from bipolar patients from those of normal,
 | unaffected individuals, schizophrenic individuals,
 | and unipolar (depressive) individuals. The diagnostic
 | assay of the invention may also or instead exploit

the similarity of cells from bipolar patients to those of people already known to have a bipolar disorder. Thus, the present invention addresses the heretofore unmet need for a clinical test useful in the diagnosis of a bipolar disorder.

The present invention further provides a diagnostic assay useful in differentiating cells from unipolar (depressive) patients from those of normal, unaffected individuals, schizophrenic individuals, and bipolar individuals. This diagnostic assay may also or instead exploit the similarity of cells from unipolar patients to those of people already known to have unipolar disorder.

As shown herein, the membrane potential in cultured cells from bipolar patients is significantly different than the membrane potential in cultured cells from unaffected controls and siblings. For example, the membrane potentials of bipolar lymphoblasts are significantly hyperpolarized when compared with those of siblings and negative controls. The changes in membrane potential reflect changes in Na^+K^+ ATPase regulation that occur in cells of patients affected with a bipolar disorder.

In preferred embodiments, a diagnostic assay for a bipolar disorder according to the invention utilizes changes in membrane potential in lymphoblasts or whole blood cells; however, a diagnostic assay for a bipolar disorder according to the invention can also employ changes in membrane potential in lymphocytes, erythrocytes, as well as in other cells.

In additional embodiments, Na^+K^+ ATPase activity and therefore membrane potential is manipulated by

incubating cells in K^+ -free buffer and/or with one or more compounds that alter the Na^+ and K^+ ionic gradients in the cells. Comparisons between cells from bipolar patients and control cells from unaffected individuals (negative controls) incubated under corresponding conditions reveal significant differences that can be quantified and used to diagnose a bipolar disorder. Likewise, comparisons between cells from bipolar patients and cells from other individuals known to have a bipolar disorder (positive controls) incubated under corresponding conditions reveal a lack of a significant difference that can be used to diagnose a bipolar disorder.

Unipolar disorder may be diagnosed in a similar manner. For example, comparisons between cells from unipolar patients and control cells from unaffected individuals (negative controls) incubated under corresponding conditions reveal significant differences that can be quantified and used to diagnose unipolar disorder. Likewise, comparisons between cells from unipolar patients and cells from other individuals known to have unipolar disorder incubated under corresponding conditions reveal a lack of a significant difference that can be used to diagnose unipolar disorder.

In a preferred embodiment, a diagnostic assay for unipolar disorder according to the invention utilizes changes in membrane potential in whole blood cells; however, a diagnostic assay for unipolar disorder can also employ changes in membrane potential in lymphoblasts, lymphocytes, erythrocytes, as well as in other cells.

The membrane potential of a patient's cells can be ascertained by any conventional method, such as by measuring the fluorescence intensity of a lipophilic fluorescent dye. For example, membrane potentials may be measured using 3,3'-dihexyloxacarbocyanine iodide DiOC₆(3), a cell-permeant, voltage sensitive, green-fluorescent dye, in conjunction with a fluorescence spectrometer.

10 **Brief Description of the Drawings**

Figure 1 shows the membrane potentials of affected (bipolar_I) lymphoblasts, non-affected sibling lymphoblasts, and normal lymphoblasts, as indicated by fluorescence intensity of DiOC₆(3) (7 nM), in regular buffer containing K⁺.

Figure 2 shows the membrane potentials of affected (bipolar_I) cells and unaffected cells, as indicated by the fluorescence intensity of DiOC₆(3) in affected cells and the combination of non-affected sibling cells and normal cells.

Figure 3 shows the fluorescence intensity of DiOC₆(3) in affected (bipolar_I) cells and unaffected (sibling and normal) cells relative to the fluorescence intensity of DiOC₆(3) in normal control cell N1.

Figure 4 shows a comparison of membrane potentials in K⁺-free buffer and in buffer containing K⁺, as indicated by the ratio of fluorescence intensity of DiOC₆(3) in affected (bipolar_I) cells and unaffected (sibling and normal) cells in K⁺-free buffer and in K⁺-containing (regular) buffer.

Figure 5 shows ethacrynate-induced changes in membrane potential, as indicated by the relative

ratio of the fluorescence intensity and therefore of
 | the membrane potential of affected (bipolar_I) cells
 and unaffected (sibling and normal) cells in K⁺-free
 buffer and in K⁺-containing (regular) buffer in the
 5 presence or absence of 30 μ M ethacrynate.

Figure 6 shows the effect of ethacrynate on
 membrane potential, as indicated by the ratio of
 | fluorescence intensity of affected (bipolar_I) cells
 and unaffected (sibling and normal) cells in K⁺-free
 10 buffer with or without the addition of 30 μ M
 ethacrynate.

Figure 7 shows the relative rate of
 | polarization of affected (bipolar_I) cells and
 unaffected (sibling and normal) cells incubated for
 15 30 minutes in K⁺-free buffer and in K⁺-containing
 (regular) buffer in the presence or absence of 30 μ M
 ethacrynate.

Figure 8 shows the effect of monensin on
 membrane potential, as indicated by the ratio of
 20 | fluorescence intensity of affected (bipolar_I) cells
 and unaffected (sibling and normal) cells in K⁺-free
 buffer with or without the addition of 10 μ M
 monensin.

Figure 9 shows the effect of phorbol 12-
 25 myristate 13-acetate (PMA) on the rate of
 repolarization, as indicated by the ratio of
 | repolarization rate of affected (bipolar_I) cells
 and unaffected (sibling and normal) cells in K⁺-free
 buffer with or without 2 μ M PMA.

30 Figure 10 shows the effect of PMA on the
 relative ratio of repolarization rates, as indicated
 by the ratio of repolarization rate of affected
 | (bipolar_I) cells and unaffected (sibling and

normal) cells in both K^+ -free buffer and in K^+ -containing (regular) buffer with or without 2 μM PMA.

Figure 11 shows the effect of lithium on
5 membrane potential, as indicated by the relative
ratio of the fluorescence intensity of affected
(bipolar__I) cells and unaffected (sibling and
normal) cells in K^+ -containing (regular) buffer and
in K^+ -free buffer in the presence or absence of 20 mM
10 lithium chloride.

Figure 12 shows the ratio of fluorescence
intensities and therefore membrane potentials in K^+ -
free buffer containing 30 μM ethacrynate to the
fluorescence intensity in K^+ -containing buffer
15 without ethacrynate in an open clinical trial using
whole blood samples.

Figure 13 shows a comparison of ethacrynate and
sorbitol in K^+ -free buffer, as used in the open
clinical trial using whole blood samples.

Figure 14 shows the ratio of fluorescence
20 intensities and therefore membrane potentials in K^+ -
free buffer containing 30 μM ethacrynate to the
fluorescence intensity in K^+ -containing buffer
without ethacrynate in a blind clinical trial using
25 whole blood samples from 18 normal controls,
10 schizophrenics, 11 unipolars, and 20 bipolars.

Figure 15 provides an example of the use of
ANOVA in the diagnosis of a representative patient
("Patient A") as bipolar. The ratio of fluorescence
30 intensities and therefore membrane potentials in K^+ -
free buffer containing 30 μM ethacrynate was
compared to the fluorescence intensity in K^+ -
containing buffer without ethacrynate.

Detailed Description of the Invention

The present invention provides a method for
 | diagnosing a patient with a bipolar disorder by
 | comparing the membrane potential of cells of the
 5 | patient with corresponding control cells of one or
 | more people known not to have a bipolar disorder
 | (negative controls) and/or corresponding bipolar
 | control cells of one or more people known to have a
 | bipolar disorder (positive controls). In experiments
 10 | described herein, the membrane potentials of
 | lymphoblasts and whole blood cells are ascertained
 | and compared. However, a diagnostic assay according
 | to the present invention can utilize any cell type,
 | such as, but not limited to, erythrocytes,
 15 | platelets, leukocytes, macrophages, monocytes,
 | dendritic cells, fibroblasts, epidermal cells,
 | mucosal tissue cells, cells in the cerebrospinal
 | fluid, hair cells, etc. Cells present in blood,
 | skin cells, hair cells, or mucosal tissue cells may
 20 | be more convenient to use because of the ease of
 | harvesting these cell types.

| For purposes of a diagnostic assay for a
 | bipolar disorder disclosed herein, "corresponding
 | control cells" means that the cells of the patient
 25 | are the same type of cells as the control cells of
 | the people known to not have a bipolar disorder.
 | Similarly, for purposes of a diagnostic assay for
 | unipolar disorder disclosed herein, "corresponding
 | control cells" means that the cells of the patient
 30 | are the same type of cells as the control cells of
 | the people known to not have unipolar disorder.
 | For example, if the cells of the patient are
 | lymphoblasts, the "corresponding control cells" are

lymphoblasts. Likewise, if the cells of the patient are whole blood cells, the "corresponding control cells" are whole blood cells.

5 | For purposes of a diagnostic assay for a
bipolar disorder disclosed herein, "corresponding
bipolar control cells" means that the cells of the
patient are the same type of cells as the bipolar
| control cells of the people known to have a bipolar
disorder. For example, if the cells of the patient
10 are lymphoblasts, the "corresponding bipolar control
cells" are lymphoblasts. Likewise, if the cells of
the patient are whole blood cells, the
"corresponding bipolar control cells" are whole
blood cells.

15 For purposes of a diagnostic assay for unipolar
disorder disclosed herein, "corresponding unipolar
control cells" means that the cells of the patient
are the same type of cells as the unipolar control
cells of the people known to have unipolar disorder.
20 For example, if the cells of the patient are whole
blood cells, the "corresponding unipolar control
cells" are whole blood cells. Likewise, if the
cells of the patient are lymphoblasts, the
"corresponding unipolar control cells" are
25 lymphoblasts.

In a preferred embodiment, a diagnostic assay
according to the present invention involves
manipulating the membrane potential in cells by
either incubating cells with a compound that alters
30 ATPase activity and/or by incubating cells in
potassium-free media. The membrane potential of the
cells is then ascertained following such treatment.

As indicated above, a cell's membrane potential is the result of the different concentration of ions on either side of the membrane. The activity of the Na^+K^+ ATPase pump, which regulates the concentration of Na^+ and K^+ to maintain homeostasis, can be altered by a variety of external stimuli, including various chemicals. When the Na^+ and K^+ ionic gradients are modulated by some means, the cell regulates the activity of the Na^+K^+ ATPase in an effort to return the ionic gradients to normal levels. Some compounds, such as ethacrynate, monensin, and monensin decyl ester, alter the activity of the Na^+K^+ ATPase by increasing the intracellular levels of sodium. Other compounds, such as phorbol 12-myristate 13-acetate (PMA), 12-O-tetradecanoylphorbol 13-acetate, phorbol 12-myristate 13-acetate 4-O-methyl ether, phorbol 12,13-dibutyrate (PDBu), phorbol 12,13-didecanoate (PDD), phorbol 12,13-dinonanoate 20-homovanillate, and other phorbol esters alter the activity of the Na^+K^+ ATPase by increasing the density of the Na^+K^+ ATPase on the cell surface. Thus, the activity of the Na^+K^+ ATPase is affected by its structure, its density, and compounds (both endogenous and exogenous) that affect the structure and density. Genes may play a role also.

Table 1 below shows other examples of compounds that alter the activity of the Na^+K^+ ATPase, either indirectly by altering the K^+ and/or Na^+ ionic gradients or by acting on the Na^+K^+ ATPase itself.

TABLE 1

<u>Chemical</u>	<u>K⁺</u>	<u>Na⁺</u>	<u>K⁺ & Na⁺</u>	<u>Na⁺K⁺ ATPase</u>
Valinomycin	X			
Monensin		X		
Gramicidin		X		
PCMBS		X		
Veratridine		X		
Ethacrynate			X	
PMA				X
Dopamine				X
Catacholamines				X
Phorbol Esters				X
Ouabain				X
Lithium	X	X	X	X
Valproate				X
Lamotrigine				X
Cocaine			X	
Nicotine		X		
R0-31-8220				X
Oxymetazoline				X
Calcineurin				X
Topiramate				X
Peptide Hormones				X
Sorbitol				
Diuretics			X	

5 In several embodiments, an assay according to the present invention employs such Na⁺K⁺ ATPase-altering compounds to help diagnose patients with a bipolar disorder. In other embodiments, an assay according to the present invention employs such Na⁺K⁺ ATPase-altering compounds to help diagnose patients with unipolar disorder.

10 The compounds that are described herein are merely examples of the compounds that could be used to alter Na⁺K⁺ ATPase activity. For example, any compound that increases the density and/or activity of the Na⁺K⁺ ATPase can be used in a diagnostic assay according to the present invention.

In another embodiment, a compound that decreases the density and/or activity of the Na^+K^+ ATPase may be used in a diagnostic assay according to the present invention. For example, low
5 concentrations of ouabain may be useful in differentiating bipolar cells from normal cells.

Thus, for purposes of this disclosure, "alters Na^+K^+ ATPase activity" includes directly altering Na^+K^+ ATPase activity by acting directly upon the
10 Na^+K^+ ATPase as well as indirectly altering Na^+K^+ ATPase activity by, for example, increasing the intracellular sodium concentration. Furthermore, "alters Na^+K^+ ATPase activity" includes increasing or decreasing Na^+K^+ ATPase activity, although increasing
15 Na^+K^+ ATPase activity is preferred.

Potassium uptake in cells of bipolar patients is significantly reduced compared to potassium uptake in cells of normal, unaffected patients. In several embodiments of the present invention, the
20 membrane potential of cells incubated in potassium-free buffer is ascertained with or without incubation with compounds that alter the activity of the Na^+K^+ ATPase.

Examples of buffers that may be used in a
25 diagnostic assay according to the present invention, along with their useful pH ranges, are shown in Table 2 below.

TABLE 2

<u>Composition</u>	<u>Lower pH</u>	<u>Upper pH</u>
Glycyl-glycine-piperazine-2HCl-NaOH	4.4	10.8
MES-NaOH-NaCl	5.2	7.1
TRIS-malic acid-NaOH	5.2	8.6
MES-NaOH	5.6	6.8
ADA-NaOH-NaCl	5.6	7.5
ACES-NaOH-NaCl	5.9	7.8
ACES-NaOH-NaCl	5.9	7.8
BES-NaOH-NaCl	6.2	8.1
MOPS-NaOH-NaCl	6.25	8.15
TES-NaOH-NaCl	6.55	8.45
MOPS-KOH	6.6	7.8
HEPES-NaOH-NaCl	6.6	8.5
TRIS-HCl	7.0	9.0
HEPPSO-NaOH	7.4	8.4
BICINE-NaOH-NaCl	7.4	9.3
TAPS-NaOH-NaCl	7.45	9.35
HEPPS (EPPS)-NaOH	7.5	8.7
TRICINE-NaOH	7.6	8.6
BICINE-NaOH	7.7	8.9

5 Potassium-containing buffers that may be used
 in a diagnostic assay according to the present
 invention can be created by adding potassium to the
 buffers shown in the table above that do not contain
 potassium. Potassium-containing buffers useful in a
 diagnostic assay according to the present preferably
 10 have a K^+ concentration in the range of approximately
 2mM to 7mM, more preferably have a K^+ concentration
 of approximately 5mM, and still more preferably have
 a K^+ concentration of 5mM.

15 The K^+ -containing buffer used in the examples
 set forth below is a HEPES buffer to which potassium
 has also been added (5 mM KCl, 4 mM $NaHCO_3$, 5 mM
 HEPES, 134 mM NaCl, 2.3 mM $CaCl_2$, and 5 mM glucose;
 pH 7.3 - 7.5, preferably 7.4), and is also referred
 to as "regular" or "stock" buffer. The K^+ -free

buffer used in the examples is a HEPES buffer without potassium (4 mM NaHCO_3 , 5 mM HEPES, 134 mM NaCl , 2.3 mM CaCl_2 , and 5 mM glucose; pH 6.6 - 7.0, preferably 7.8).

5 The membrane potential of a patient's cells may be ascertained by any conventional method, such as by examining the fluorescence intensity of a potential-sensitive lipophilic fluorescent dye. The membrane potential is directly proportional to the
10 intensity of fluorescence according to the following equation: $I = CV$, wherein I is the fluorescence intensity of a lipophilic fluorescent dye, V is the voltage or membrane potential, and C is a constant that can vary depending on a number of factors such
15 as, but not limited to, temperature, lamp intensity, number of cells, concentration of the fluorescent dye, incubation time, and lipid composition of cells used. The calibration and determination of the value for C can be a cumbersome and unreliable procedure.
20 Thus, according to the present invention, by using the ratio of the fluorescence intensity (I_1) of one sample of cells to the fluorescence intensity (I_2) of another sample of cells, the constant (C) is canceled out. Such ratio-metric measurements are
25 preferred over absolute measurements.

 Examples of potential-sensitive dyes that may be adapted for use in a diagnostic assay according to the present invention, along with their charges and optical responses, are shown below in Table 3
30 (all available from Molecular Probes Inc., Eugene, OR, US).

TABLE 3

<u>Dye</u>	<u>Structure</u> <u>(Charge)</u>	<u>Optical Response</u>
DiOC ₂ (3) DiOC ₅ (3) DiOC ₆ (3) DiSC ₃ (5) DiIC ₁ (5)	Carbocyanine (cationic)	Slow; fluorescence response to depolarization depends on staining concentration and detection method.
JC-1 JC-9	Carbocyanine (cationic)	Slow; fluorescence emission ratio 585/520 nm increases upon membrane hyperpolarization.
Tetramethyl-rhodamine methyl and ethyl esters Rhodamine 123	Rhodamine (cationic)	Slow; used to obtain unbiased images of potential-dependent dye distribution.
Oxonol V Oxonol VI	Oxonol (anionic)	Slow; fluorescence decreases upon membrane hyperpolarization.
DiBAC ₄ (3) DiBAC ₄ (5) DiSBAC ₂ (3)	Oxonol (anionic)	Slow; fluorescence decreases upon membrane hyperpolarization.
Merocyanine 540	Merocyanine	Fast/Slow (biphasic response).

Indo- (DiI), thia- (DiS) and oxa- (DiO)
 5 carbocyanines with short alkyl tails (<7 carbon atoms) were among the first potentiometric fluorescent probes developed. These cationic dyes accumulate on hyperpolarized membranes and are translocated into the lipid bilayer. DiOC₆(3) (3,3'-
 10 dihexyloxacarbocyanine iodide), a cell-permeant, voltage sensitive, green-fluorescent dye, has been the most widely used carbocyanine dye for membrane potential measurements, followed closely by DiOC₅(3). Thus, in a preferred embodiment of a diagnostic
 15 assay according to the present invention, membrane

potentials may be measured using DiOC₆(3) in conjunction with a fluorescence spectrometer.

One embodiment of the present invention involves a direct comparison of membrane potentials
5 between cells of a patient in need of a bipolar disorder diagnosis and control cells. See, e.g., Example 2 and Figure 2. In particular, this embodiment provides a method for diagnosing a
bipolar disorder in a patient, comprising:

10 (a) ascertaining the mean membrane potential of cells of the patient; and one or both of the following steps (b) and (c):

(b) comparing the mean membrane potential of the cells of the patient with the mean membrane
15 potential of corresponding control cells of one or more people known to not have said bipolar disorder, wherein a significant difference between the mean membrane potential of the cells of the patient and the mean membrane potential of corresponding control
20 cells indicates that the patient has said bipolar disorder;

(c) comparing the mean membrane potential of the cells of the patient with the mean membrane potential of corresponding bipolar control cells of
25 one or more people known to have said bipolar disorder, wherein the lack of a significant difference between the mean membrane potential of the cells of the patient and the mean membrane potential of the corresponding bipolar control cells
30 indicates that the patient has said bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c)

are performed. In another embodiment, steps (a), (b) and (c) are performed.

A preferred embodiment of the present invention involves a comparison of the ratios of membrane potentials in K^+ -free buffer to those in K^+ -containing buffer. See, for example, Example 3 and Figure 4. In particular, this embodiment provides a method for diagnosing a bipolar disorder in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the absence of K^+ to (ii) the mean membrane potential of cells of the patient incubated in the presence of K^+ ; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the absence of K^+ to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the presence of K^+ , wherein a significant difference between the patient ratio compared to the control ratio indicates that the patient has said bipolar disorder;

(c) comparing the patient ratio obtained in (a) to a bipolar control ratio, wherein the bipolar control ratio is the ratio of (v) the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the absence of K^+ to (vi) the

mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the presence of K^+ , wherein the lack of a significant difference
5 between the patient ratio and the bipolar control ratio indicates that the patient has said bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c)
10 are performed. In another embodiment, steps (a), (b) and (c) are performed.

In a preferred embodiment, the significant difference between the patient ratio compared to the control ratio is that the patient ratio is
15 significantly higher than the control ratio.

These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

20

patient ratio:

(i) mean membrane potential of cells of the
patient incubated in the absence of K^+

5 (ii) mean membrane potential of cells of the
patient incubated in the presence of K^+

compared to:

10 control ratio:

(iii) mean membrane potential of
corresponding control cells incubated in the
absence of K^+

15 (iv) mean membrane potential of
corresponding control cells incubated in the
presence of K^+

and/or compared to:

20 bipolar control ratio:

(v) mean membrane potential of corresponding
bipolar control cells incubated in the
absence of K^+

25 (vi) mean membrane potential of
corresponding bipolar control cells
incubated in the presence of K^+ .

30 According to the above, when K^+ is present, it
is preferably present at a concentration of
approximately 2 - 7 mM, more preferably at a
concentration of approximately 5mM, and still more
preferably at a concentration of 5mM.

35 In another embodiment, the cells of the patient
are incubated in the presence of a compound that
alters Na^+K^+ ATPase activity; and the corresponding
control cells, the corresponding bipolar control
cells, or both the corresponding control cells and
40 the corresponding bipolar control cells are also
incubated in the presence of the compound that
alters Na^+K^+ ATPase activity.

Yet another preferred embodiment of the present invention involves a comparison of the ratio of membrane potential with and without a Na^+K^+ ATPase-altering compound. See, e.g., Example 5 and Figure 8, and Example 10 and Figure 15. In particular, this embodiment provides a method for diagnosing a bipolar disorder in a patient, comprising:

(a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na^+K^+ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of the compound that alters Na^+K^+ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the presence of a compound that alters Na^+K^+ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the absence of the compound that alters Na^+K^+ ATPase activity, wherein a significantly lower patient ratio compared to the control ratio indicates that the patient has said bipolar disorder;

(c) comparing the patient ratio obtained in (a) to a bipolar control ratio, wherein the bipolar control ratio is the ratio of (v) the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the presence of a compound

that alters Na^+K^+ ATPase activity to (vi) the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the absence of the
5 compound that alters Na^+K^+ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the bipolar control ratio indicates that the patient has said bipolar disorder.

10 In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

These comparative ratios, wherein the patient
15 ratio is compared to the control ratio and/or the bipolar control ratio, can be illustrated as follows:

patient ratio:

(i) mean membrane potential of cells of the
patient incubated in the presence of a
compound that alters Na^+K^+ ATPase activity

5

(ii) mean membrane potential of cells of the
patient incubated in the absence of the
compound that alters Na^+K^+ ATPase activity

10 compared to:

control ratio:

(iii) mean membrane potential of
corresponding control cells incubated in the
presence of a compound that alters Na^+K^+
ATPase activity

15

(iv) mean membrane potential of
corresponding control cells incubated in the
absence of the compound that alters Na^+K^+
ATPase activity

20

and/or compared to:

bipolar control ratio:

(v) mean membrane potential of corresponding
bipolar control cells incubated in the
presence of a compound that alters Na^+K^+
ATPase activity

25

(vi) mean membrane potential of
corresponding bipolar control cells
incubated in the absence of the compound
that alters Na^+K^+ ATPase activity.

30

35 In one embodiment, the cells are incubated in
the presence of K^+ , wherein the K^+ concentration is
preferably approximately 2 - 7 mM, more preferably
approximately 5mM, and still more preferably 5mM. In
another embodiment, the cells are incubated in the
40 absence of K^+ . Preferably, the cells incubated in the
presence of a compound that alters Na^+K^+ ATPase
activity are incubated in the absence of K^+ , and the

cells incubated in the absence of the compound that alters Na^+K^+ ATPase activity are incubated in the presence of K^+ .

Still another preferred embodiment of the present invention involves a comparison of the relative ratios of membrane potentials in K^+ -free buffer to those in K^+ -containing buffer with and without a Na^+K^+ ATPase-altering compound. See, e.g., Examples 4 and 7 and Figures 5 and 11. In particular, this embodiment provides a method for diagnosing a bipolar disorder in a patient, comprising:

(a) obtaining a ratio (patient ratio I) of (i) the mean membrane potential of cells of the patient incubated in the absence of K^+ and in the presence of a compound that alters Na^+K^+ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of K^+ and in the absence of the compound that alters Na^+K^+ ATPase activity;

(b) obtaining a ratio (patient ratio II) of (iii) the mean membrane potential of cells of the patient incubated in the presence of K^+ and in the presence of the compound that alters Na^+K^+ ATPase activity to (iv) the mean membrane potential of cells of the patient incubated in the presence of K^+ and in the absence of the compound that alters Na^+K^+ ATPase activity;

(c) obtaining a relative ratio (Relative Patient Ratio) of patient ratio I to patient ratio II; and one or both of the following steps (d) and (e):

(d) comparing the Relative Patient Ratio to a Relative Control Ratio, wherein the Relative Control Ratio is the relative ratio of control ratio I to

control ratio II, wherein control ratio I is the ratio of (i') the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the absence of K^+ and in the presence of a compound that alters Na^+K^+ ATPase activity to (ii') the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the absence of K^+ and in the absence of the compound that alters Na^+K^+ ATPase activity, and wherein control ratio II is the ratio of (iii') the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the presence of K^+ and in the presence of the compound that alters Na^+K^+ ATPase activity to (iv') the mean membrane potential of corresponding control cells of one or more people known to not have said bipolar disorder incubated in the presence of K^+ and in the absence of the compound that alters Na^+K^+ ATPase activity, wherein a significant difference between the Relative Patient Ratio compared to the Relative Control Ratio indicates that the patient has said bipolar disorder;

(e) comparing the Relative Patient Ratio to a Relative Bipolar Control Ratio, wherein the Relative Bipolar Control Ratio is the relative ratio of bipolar control ratio I to bipolar control ratio II, wherein bipolar control ratio I is the ratio of (i'') the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the absence of K^+ and in the presence of a compound that alters

Na⁺K⁺ ATPase activity to (ii'') the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the absence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, and wherein bipolar control ratio II is the ratio of (iii'') the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the presence of K⁺ and in the presence of the compound that alters Na⁺K⁺ ATPase activity to (iv'') the mean membrane potential of corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the presence of K⁺ and in the absence of the compound that alters Na⁺K⁺ ATPase activity, wherein the lack of a significant difference between the Relative Patient Ratio compared to the Relative Bipolar Control Ratio indicates that the patient has bipolar disorder.

In one embodiment, steps (a), (b), (c), and (d) are performed. In another embodiment, steps (a), (b), (c), and (e) are performed. In another embodiment, steps (a), (b), (c), (d), and (e) are performed.

In a preferred embodiment, the significant difference between the Relative Patient Ratio and the Relative Control Ratio is that the Relative Patient Ratio is significantly higher than the Relative Control Ratio.

These comparative ratios, wherein the Relative Patient Ratio is compared to the Relative Control Ratio and/or the Relative Bipolar Control Ratio, can be illustrated as follows:

Relative Patient Ratio:

patient ratio I:

5 (i) mean membrane potential of cells of the patient
incubated in the absence of K^+ and in the presence
of a compound that alters Na^+K^+ ATPase activity

10 (ii) mean membrane potential of cells of the patient
incubated in the absence of K^+ and in the absence of
the compound that alters Na^+K^+ ATPase activity

patient ratio II:

15 (iii) mean membrane potential of cells of the
patient incubated in the presence of K^+ and in the
presence of the compound that alters Na^+K^+ ATPase
activity

20 (iv) mean membrane potential of cells of the patient
incubated in the presence of K^+ and in the absence
of the compound that alters Na^+K^+ ATPase activity

compared to:

Relative Control Ratio:

25 control ratio I:

(i') mean membrane potential of corresponding
control cells incubated in the absence of K^+ and in
the presence of a compound that alters Na^+K^+ ATPase
activity

30 (ii') mean membrane potential of corresponding
control cells incubated in the absence of K^+ and in
the absence of the compound that alters Na^+K^+ ATPase
activity

35 control ratio II:

40 (iii') mean membrane potential of corresponding
control cells incubated in the presence of K^+ and in
the presence of the compound that alters Na^+K^+ ATPase
activity

45 (iv') mean membrane potential of corresponding
control cells incubated in the presence of K^+ and in
the absence of the compound that alters Na^+K^+ ATPase
activity

or more people known to not have said bipolar disorder incubated in the presence of the compound that alters Na^+K^+ ATPase activity, wherein a significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding control cells indicates that the patient has said bipolar disorder;

(c) comparing the mean rate of repolarization ascertained in (a) to the mean rate of repolarization in corresponding bipolar control cells of one or more people known to have said bipolar disorder incubated in the presence of the compound that alters Na^+K^+ ATPase activity, wherein the lack of a significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding bipolar control cells indicates that the patient has said bipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

In a preferred embodiment, the significant difference between the mean rate of repolarization in the cells of the patient compared to the mean rate of repolarization in the corresponding control cells is that the mean rate of repolarization in the cells of the patient is significantly higher (e.g. $P < 0.05$) than the mean rate of repolarization in the corresponding control cells.

In one embodiment, the cells are incubated in the presence of K^+ . In another embodiment, the cells

are incubated in the absence of K^+ . As used herein, "presence of K^+ " preferably means a K^+ concentration in the range of approximately 2mM to 7mM, preferably approximately 5mM. For example, the K^+ -containing
5 HEPES buffer used in the examples below has a K^+ concentration of 5mM.

In yet another embodiment, the present invention provides a method for diagnosing unipolar disorder in a patient, comprising:

10 (a) obtaining a patient ratio of (i) the mean membrane potential of cells of the patient incubated in the presence of a compound that alters Na^+K^+ ATPase activity to (ii) the mean membrane potential of cells of the patient incubated in the absence of
15 the compound that alters Na^+K^+ ATPase activity; and one or both of the following steps (b) and (c):

(b) comparing the patient ratio obtained in (a) to a control ratio, wherein the control ratio is the ratio of (iii) the mean membrane potential of
20 corresponding control cells of one or more people known to not have unipolar disorder incubated in the presence of a compound that alters Na^+K^+ ATPase activity to (iv) the mean membrane potential of corresponding control cells of one or more people
25 known to not have unipolar disorder incubated in the absence of the compound that alters Na^+K^+ ATPase activity, wherein a significantly higher patient ratio compared to the control ratio indicates that the patient has unipolar disorder;

30 (c) comparing the patient ratio obtained in (a) to a unipolar control ratio, wherein the unipolar control ratio is the ratio of (v) the mean membrane potential of corresponding unipolar control

cells of one or more people known to have unipolar disorder incubated in the presence of a compound that alters Na^+K^+ ATPase activity to (vi) the mean membrane potential of corresponding unipolar control
5 cells of one or more people known to have unipolar disorder incubated in the absence of the compound that alters Na^+K^+ ATPase activity, wherein the lack of a significant difference between the patient ratio compared to the unipolar control ratio
10 indicates that the patient has unipolar disorder.

In one embodiment, steps (a) and (b) are performed. In another embodiment, steps (a) and (c) are performed. In another embodiment, steps (a), (b) and (c) are performed.

15 These comparative ratios, wherein the patient ratio is compared to the control ratio and/or the unipolar control ratio, can be illustrated as follows:

patient ratio:

(i) mean membrane potential of cells of the
patient incubated in the presence of a
compound that alters Na^+K^+ ATPase activity

(ii) mean membrane potential of cells of the
patient incubated in the absence of the
compound that alters Na^+K^+ ATPase activity

compared to:

control ratio:

(iii) mean membrane potential of
corresponding control cells incubated in the
presence of a compound that alters Na^+K^+
ATPase activity

(iv) mean membrane potential of
corresponding control cells incubated in the
absence of the compound that alters Na^+K^+
ATPase activity

and/or compared to:

unipolar control ratio:

(v) mean membrane potential of corresponding
unipolar control cells incubated in the
presence of a compound that alters Na^+K^+
ATPase activity

(vi) mean membrane potential of
corresponding unipolar control cells
incubated in the absence of the compound
that alters Na^+K^+ ATPase activity.

In one embodiment, the cells are incubated in
the presence of K^+ , wherein the K^+ concentration is
preferably approximately 2 - 7 mM, more preferably
approximately 5mM, and still more preferably 5mM. In
another embodiment, the cells are incubated in the
absence of K^+ . Preferably, the cells incubated in the
presence of a compound that alters Na^+K^+ ATPase
activity are incubated in the absence of K^+ , and the

cells incubated in the absence of the compound that alters Na^+K^+ ATPase activity are incubated in the presence of K^+ .

In a preferred embodiment of a diagnostic assay
 5 | for a bipolar disorder or unipolar disorder
 according to the present invention, the compound
 that alters Na^+K^+ ATPase activity is a compound
 selected from the group consisting of: valinomycin,
 monensin, gramicidin, *p*-
 10 chloromercuribenzenesulfonate (PCMBS), monensin
 decyl ester, veratridine, ethacrynate, dopamine, a
 catecholamine, a phorbol ester, ouabain, lithium,
 valproate, lamotrigine, cocaine, nicotine, the
 protein kinase C inhibitor R0-31-8220 (Wilkinson et
 15 al, *Biochem. J.* 294:335-337 (1993)), oxymetazoline,
 calcineurin, topiramate, a peptide hormone,
 sorbitol, and a diuretic. Preferably, the compound
 that alters Na^+K^+ ATPase activity increases Na^+K^+
 ATPase activity.

20 | In one embodiment of a diagnostic assay for a
 bipolar disorder or a diagnostic assay for unipolar
 disorder according to the present invention, the
 compound that alters Na^+K^+ ATPase activity is
 ethacrynate. Preferably, the concentration of
 25 ethacrynate is in the range of 1 μM to 100 μM , for
 example approximately 30 μM , more preferably 30 μM .

In another embodiment of a diagnostic assay for
 | a bipolar disorder or a diagnostic assay for
 unipolar disorder according to the present
 30 invention, the compound that alters Na^+K^+ ATPase
 activity is monensin. Preferably, the concentration
 of monensin is in the range of 1 μM to 50 μM , for
 example approximately 10 μM , more preferably 10 μM .

In another embodiment of a diagnostic assay for
 | a bipolar disorder or a diagnostic assay for
 unipolar disorder according to the present
 invention, the compound that alters Na^+K^+ ATPase
 5 activity is monensin decyl ester. Preferably, the
 concentration of monensin decyl ester is in the
 range of 1 μM to 50 μM , for example approximately 10
 μM , more preferably 10 μM .

In another embodiment of a diagnostic assay for
 10 | a bipolar disorder or a diagnostic assay for
 unipolar disorder according to the present
 invention, the compound that alters Na^+K^+ ATPase
 activity is a phorbol ester. Preferably, the phorbol
 ester is selected from the group consisting of:
 15 phorbol 12-myristate 13-acetate (PMA), 12-O-
 tetradecanoylphorbol 13-acetate, phorbol 12-
 myristate 13-acetate 4-O-methyl ether, phorbol
 12,13-dibutyrate (PDBu), phorbol 12,13-didecanoate
 (PDD), and phorbol 12,13-dinonanoate 20-
 20 homovanillate. More preferably, the phorbol ester
 is phorbol 12-myristate 13-acetate (PMA).
 Preferably, the concentration of phorbol 12-
 myristate 13-acetate (PMA) is in the range of 0.1 μM
 to 10 μM , for example approximately 2 μM , more
 25 preferably 2 μM .

In another embodiment of a diagnostic assay for
 | a bipolar disorder or a diagnostic assay for
 unipolar disorder according to the present
 invention, the compound that alters Na^+K^+ ATPase
 30 activity is lithium. Preferably, the concentration
 of lithium is in the range of 1 μM to 50 μM , for
 example approximately 20 mM, more preferably 20 mM.

In another preferred embodiment of a diagnostic assay for a bipolar disorder or a diagnostic assay for unipolar disorder according to the present invention, the mean membrane potential of the cells of the patient is determined by incubating the cells of the patient with a voltage-sensitive fluorescent dye and measuring the fluorescence intensity of the fluorescent dye. Preferably, the dye is a cell-permeant cationic dye. Preferably, the dye is a carbocyanine dye. In a preferred embodiment, the dye is 3,3'-dihexyloxacarbocyanine iodide $\text{DiOC}_6(3)$. Preferably, the concentration of dye is in the range of 1 nM to 500 nM, for example approximately 7 nM, more preferably 7 nM.

In another preferred embodiment of a diagnostic assay for a bipolar disorder or a diagnostic assay for unipolar disorder according to the present invention, the cells of the patient and the corresponding control cells (and corresponding bipolar and unipolar control cells, as appropriate) are selected from the group consisting of: lymphoblasts, erythrocytes, platelets, leukocytes, macrophages, monocytes, dendritic cells, fibroblasts, epidermal cells, mucosal tissue cells, cells in the cerebrospinal fluid, hair cells, and cells in whole blood. Preferably, the cells are lymphoblasts or cells in whole blood.

As described more fully in the examples below, the ratio of membrane potentials of bipolar cells in K^+ -free buffer to membrane potentials of bipolar cells in K^+ -containing buffer is significantly different from that of unaffected cells. Cells incubated in ethacrynate (30 μM) show significant

differences between bipolar cells and unaffected cells. Cells incubated in monensin ($10\mu\text{M}$) and in PMA ($2\mu\text{M}$) also show significant differences in specific potentials. In addition to being a mood stabilizer,
5 lithium serves as a medium to distinguish between bipolar cells and unaffected cells.

Further, as shown in a clinical trial using whole blood samples from bipolar, unipolar and schizophrenic patients described more fully below,
10 the ratio of membrane potentials of bipolar cells is significantly different from that of matched control cells ($P < 0.001$). In addition, the ratio of membrane potentials of unipolar cells is significantly different from that of matched control
15 cells ($P < 0.001$).

According to the present invention, when two sample groups are compared for differences for diagnostic purposes, e.g. affected cells and unaffected cells, student's t-test is preferably
20 employed to determine if the two groups are significantly different from each other. As used herein, a "significant difference" (i.e., significantly higher or significantly lower) means that $P < 0.05$. Commercially available statistical
25 software is preferably used for this purpose.

According to the present invention, when more than two sample groups are compared to diagnose whether or not an individual patient is bipolar or unipolar, analysis of variance (ANOVA) test is
30 preferably used. (See Beth Dawson and Robert G. Trapp, Basic and Clinical Biostatistics, Lange Medical Books, McGraw-Hill 3rd Edn.) In a preferred embodiment, an individual patient's cell sample is

tested as described herein and six to twelve values are calculated. These patient values are treated as a first sample group and compared with a normal control group (negative control) and a bipolar group (positive control) as shown in Example 10. A bipolar diagnosis is made when there is a significant difference ($P < 0.05$) between the normal control group (negative control) and the patient, but there is not a significant difference between the bipolar control group (positive control) and the patient. A similar procedure is used to determine whether or not a patient is unipolar.

Although the examples below describe experiments comparing membrane potentials of patients being diagnosed for a bipolar disorder to groups of controls that were examined contemporaneously, an assay according to the invention preferably compares the mean membrane potential of a patient's cells to predetermined control value or values. Thus, the standard control value(s) do not need to be determined contemporaneously with every patient assay for a bipolar disorder, but are preferably pre-determined for later comparisons with patients being diagnosed. Although not contemporaneous, assay conditions between patients and controls are preferably the same. Preferably, control data is pre-determined from various types of corresponding control cells, so that regardless of the type of cells from a patient being tested, control information already exists with which to make a comparison and thus a diagnosis. Furthermore, control data is preferably pre-determined using a control group known not to

have any mental illness, in addition to control groups having mental illnesses such as a bipolar disorder, unipolar disorder, or schizophrenia.

The instant disclosure demonstrates that manipulation of Na^+K^+ ATPase activity provides an effective tool for differentiating bipolar cells from non-bipolar cells. Novel diagnostic assays for a bipolar disorder are thus provided. The instant disclosure also demonstrates that manipulation of Na^+K^+ ATPase activity is an effective tool for differentiating unipolar cells from non-unipolar cells, and therefore provides diagnostic assays for unipolar disorder. The specificity and sensitivity of the diagnostic assays described herein compare well with state-of-the-art diagnostic techniques for various other diseases.

The following examples are provided for illustrative purposes only and are in no way intended to limit the scope of the invention.

Examples**Example 1****Cell Cultures**

5 Three groups of immortalized lymphoblast
 samples were obtained from the Human Genetic Mutant
 Cell Repository (Coriell Institute for Medical
 Research, Camden NJ). The samples are shown in
 Table 4 below and included six from affected
 10 | (bipolar I disorder) patients (A1 through A6), six
 from their siblings (S1 through S6), and six from
 unrelated normal control subjects matched by age and
 sex (N1 through N6).

TABLE 4

<u>Name</u>	<u>Coriell Number</u>	<u>Age</u>	<u>Sex</u>
A1	<u>GM05977</u> GM09869	26 yr	Male
A2	<u>GM05999</u> GM05977	22 yr	Female
A3	<u>GM05918</u> GM05999	26 yr	Female
A4	<u>GM06003</u> GM05918	16 yr	Female
A5	<u>GM11051</u> GM06003	35 yr	Female
A6	<u>GM05933</u> GM11051	25 yr	Female
S1	<u>GM05914</u> GM05933	23 yr	Male
S2	<u>GM05901</u> GM05914	28 yr	Female
S3	<u>GM09215</u> GM05901	50 yr	Male
S4	<u>GM05888</u> GM09215	18 yr	Male
S5	<u>GM05901</u> GM05888	28 yr	Female
S6	<u>GM05945</u> GM05901	55 yr	Female
N1	<u>GM06160</u> GM05945	25 yr	Male
N2	<u>GM05408</u> GM06160	28 yr	Female
N3	<u>GM06862</u> GM05408	34 yr	Female
N4	<u>GM06051</u> GM06862	26 yr	Female
N5	<u>GM06861</u> GM06051	36 yr	Male
N6	<u>GM09869</u> GM06861	36 yr	Male

15

The cells were grown at 37°C in RPMI 1640
 culture medium (GIBCO, Life Technologies,
 Gaithersburg, MD, USA) with 15% fetal bovine serum
 and 1% penicillin.

Example 2Determination of Membrane Potential

The membrane potentials of the bipolar I cells shown in Table 4 above (as well as in all other experiments, except where indicated) were measured using the following protocol. The cells cultured in the media described above were centrifuged at 210g for 5 minutes at room temperature, then suspended in 3 ml of K⁺-containing stock buffer (5 mM KCl, 4 mM NaHCO₃, 5 mM HEPES, 134 mM NaCl, 2.3 mM CaCl₂, and 5 mM glucose). The cells were counted and the desired number of cells were again suspended in the K⁺-containing buffer. The membrane potentials were measured using 3,3'-dihexyloxacarbocyanine iodide DiOC₆(3), a cell-permeant, voltage sensitive, green-fluorescent dye (Molecular Probes Inc. Eugene, OR USA). The cells were preincubated for 30 minutes before measurements. The preincubated cell suspension was centrifuged at 210 g for 5 minutes and the cells were resuspended in the K⁺-containing buffer without the dye in the buffer.

A fluorescence spectrometer (F2500 Hitachi, Japan) was used for the measurement of the membrane potential by measuring the fluorescence intensity of DiOC₆(3), which is directly proportional to the membrane potential. The intensity of fluorescence was measured at an excitation wavelength of 488 nm and an output wavelength of 540 nm. The time of recordings varied from 10 seconds to 1500 seconds depending upon the experiment.

Membrane potential was expressed according to fluorescence intensity using the following equation: $I = CV$, wherein I is the fluorescence intensity of a

lipophilic fluorescent dye DiOC₆(3) being only one example of such a dye); V is the voltage or membrane potential; and C is a constant that can vary depending on a number of factors such as, but not limited to, temperature, lamp intensity, number of cells, concentration of the fluorescent dye, incubation time, and lipid composition of cells used. By using the ratio of the fluorescence intensity (I₁) of one sample of cells to the fluorescence intensity (I₂) of another sample of cells, the constant (C) could be canceled out

The measurements of the fluorescence intensity (and thereby membrane potential, per the above equation) indicated that the mean membrane potential of the affected (bipolar_I) cells was statistically distinguishable from that of the other cells. Figure 1 shows box plots of the membrane potentials of lymphoblasts from the three groups tested, namely the affected (bipolar_I) cells, non-affected sibling cells, and normal cells, as indicated by the fluorescence intensity of DiOC₆(3) (7 nM) in K⁺-containing (regular) buffer. The differences in the mean values among the groups were greater than would be expected by chance. The mean fluorescence intensity of the affected (bipolar_I) cells was significantly lower (P < 0.001) by a one-way ANOVA test than that of the sibling cells as well as that of the normal control cells. There was no significant difference between normal cells and sibling cells. The box plots show the 5th, 25th, 50th, 75th, and 95th percentile lines. The mean and median lines coincide for the affected cells, but are separated for the other two cell lines. Power of

performed test with $\alpha = 0.050$: 0.991. $N = 6$.
Data points = 57.

A post-hoc comparison showed a significant
difference between affected (bipolar_I) cells vs.
5 normal cells and sibling cells, but not between
sibling cells and normal cells. Therefore sibling
cells and normal cells were combined into a single,
"unaffected" category. Figure 2 shows the membrane
potentials of affected (bipolar_I) cells and
10 unaffected cells, as indicated by the fluorescence
intensity of DiOC₆(3) in affected cells and in the
combination of non-affected sibling cells and normal
cells. The difference in the mean values of the
resulting two groups was greater than would be
15 expected by chance. The mean fluorescence intensity
of the affected (bipolar_I) cells was significantly
lower ($P < 0.001$) than that of the unaffected cells.
95 percent confidence interval for difference of
means: -159.577 to -66.090. Power of performed test
20 with $\alpha = 0.050$: 0.999.

An additional ratio-metric comparison was made
by plotting a ratio of fluorescence intensities of
the tested cells to that of a cell selected as a
standard. Figure 3 shows the fluorescence intensity
25 of DiOC₆(3) in affected (bipolar_I) cells and
unaffected (sibling and normal) cells relative to
the fluorescence intensity of DiOC₆(3) in the control
cell, N1. This ratio-metric procedure accounted for
variations in cell count and dye concentration. The
30 difference in the mean values of the resulting two
groups was greater than would be expected by chance.
The mean relative intensity of the affected (bipolar
I) cells was significantly lower ($P < 0.001$) than

that of the unaffected cells. $t = -5.386$ with 54 degrees of freedom. Power of performed test with $\alpha = 0.050$: 1.000.

The data presented in this example and shown in
 5 Figures 1-3 indicates that the membrane potential of
 cells such as lymphoblasts can be used to
 distinguish groups of patients with bipolar I
 disorder from groups of unaffected controls.

Example 3

Membrane Potential In K^+ -free Buffer

Membrane potentials were also measured in K^+ -
 free buffer to enable comparison with membrane
 potentials in K^+ -containing buffer. As used herein,
 15 K^+ -free buffer contains all of the components of the
 K^+ -containing buffer, except potassium (4 mM $NaHCO_3$,
 5 mM HEPES, 134 mM $NaCl$, 2.3 mM $CaCl_2$, and 5 mM
 glucose). Constant volumes of samples of each cell
 line were added to an equal volume of buffer
 20 containing an equal volume of dye. K^+ -free buffer as
 well as K^+ -containing buffer contained an equal
 volume of cells (and hence an equal number of cells
 from that culture sample) and an equal concentration
 of dye. Each variable was constant for each cell
 25 line in both buffers, so that the ratio of
 intensities was a true ratio-metric measurement.

Figure 4 shows a comparison of membrane
 potentials in K^+ -free buffer with those in K^+ -
 containing (regular) buffer, as indicated by
 30 fluorescence intensity. 70 nM $DiOC_6(3)$ was added to
 the cells 30 minutes prior to measuring the membrane
 potential. The ratio of fluorescence intensity of
 $DiOC_6(3)$ in K^+ -free buffer to the fluorescence

intensity of DiOC₆(3) in K⁺-containing buffer was plotted in the y-axis. The mean value of the ratio of the membrane potential of affected cells was approximately 0.71. In comparison, the mean value of the ratio of the membrane potential of the unaffected cells was approximately 0.51. The ratio of the membrane potential of the unaffected cells was significantly lower than that in affected cells, as indicated by t-test (P = 0.020).

The above procedure was also used for the ratio-metric measurements described below.

Example 4

Ethacrynate-Induced Changes In Membrane Potential

Ethacrynate is a loop diuretic prescribed for kidney patients that increases the intracellular sodium concentration and decreases the intracellular potassium concentration. When the intracellular sodium concentration increases, cells correspondingly regulate Na⁺K⁺ ATPase activity to pump the extra sodium out of the cells. Thus, these changes initiate the Na⁺K⁺ ATPase activity to normalize the ionic gradients.

The relative fluorescence intensity ratio of cells in K⁺-free buffer was compared to that of cells in K⁺-containing buffer with or without 30 μM ethacrynate. The cells were incubated with or without ethacrynate (30 μM) for 30 min in K⁺-containing buffer or in K⁺-free buffer. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The intensity ratio (membrane potential with ethacrynate/membrane potential without ethacrynate)

was compared to the intensity ratio in K^+ -containing buffer and/or in K^+ -free buffer. The relative intensity ratio was obtained by dividing the intensity ratio in K^+ -free buffer by the intensity
 5 ratio in K^+ -containing buffer.

A constant sample volume of each cell line was added to an equal volume of each buffer containing an equal volume of dye. Thus, the K^+ -free buffer and the K^+ -containing buffer contained an equal number of
 10 cells from each culture sample and an equal concentration of dye.

As shown in Figure 5, the relative intensity ratio of affected cells was significantly higher than that of unaffected cells by t-test. The mean
 15 value of the ratio of the fluorescence intensity of affected cells in K^+ -free buffer to the fluorescence intensity of affected cells in K^+ -containing (regular) buffer was approximately 1.04. The mean value of the ratio of fluorescent intensity of the
 20 unaffected cells in K^+ -free buffer to the fluorescence intensity of unaffected cells in K^+ -containing buffer was approximately 0.79. Further, the mean value of the ratio of the affected cells was statistically higher than the mean ratio of
 25 unaffected cells ($P = 0.009$).

Similar differences were found in K^+ -containing buffer alone or in K^+ -free buffer alone. The fluorescence intensity of cells incubated in K^+ -free buffer with 30 μM ethacrynate was compared to that
 30 of cells incubated in K^+ -free buffer without ethacrynate. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. As shown in Figure 6,

the intensity ratio (membrane potential of cells incubated with ethacrynate/membrane potential of cells not incubated with ethacrynate) of affected cells was significantly higher than that of unaffected cells by t-test ($P = 0.032$).

As the Na^+K^+ ATPase density on the cell surface increases, the intracellular sodium concentration decreases and the membrane potential begins to drop as a result of repolarization of the cell membrane. The rate of drop in membrane potential (repolarization rate) in affected cells incubated for 30 minutes in both K^+ -free buffer and in K^+ -containing (regular) buffer in the presence or absence of $30\ \mu\text{M}$ ethacrynate was compared to that of unaffected cells incubated for 30 minutes in both K^+ -free buffer and in K^+ -containing buffer in the presence or absence of $30\ \mu\text{M}$ ethacrynate. The difference in the median values between the two groups was greater than would be expected by chance. As shown in Figure 7, the relative rate of repolarization was significantly higher in affected cells compared to that of unaffected cells ($P = 0.041$, as determined by t-test).

Example 5

Monensin-Induced Changes In Membrane Potential

Monensin is an antibiotic ionophore having a 10-fold preference for Na^+ over K^+ . Monensin increases the intracellular sodium concentration, thus changing the ratio of membrane potentials. The increase in sodium concentration in turn leads to an increase in Na^+K^+ ATPase density.

The fluorescence intensity of cells incubated in K^+ -free buffer with 10 μM monensin was compared to that of cells incubated in K^+ -free buffer without monensin. The cells were incubated for 30 minutes. 5 The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. As shown in Figure 8, the intensity ratio (membrane potential of cells incubated with monensin/membrane potential of cells not incubated 10 with monensin) of affected cells was significantly lower than that of unaffected cells by t-test ($P = 0.009$).

Example 6

15 PMA-Induced Changes In Membrane Potential

Protein kinase C (PKC) is an essential enzyme involved in the phosphorylation of ATP, which provides energy for the Na^+K^+ ATPase. Furthermore, PKC activators such as PMA and inhibitors such as 20 dopamine significantly alter Na^+K^+ ATPase density in the presence of monensin.

The rate of drop in membrane potential after incubation with the protein kinase C (PKC) activator, phorbol 12-myristate 13-acetate (PMA), 25 was compared in affected cells to that of unaffected cells. The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The rate of drop in membrane potential (repolarization rate) in affected cells 30 was compared to that in unaffected cells in K^+ -free buffer in the presence or absence of 2 μM PMA. The difference in the median values between the two groups was greater than would be expected by chance.

The ratio of repolarization rate with PMA divided by the repolarization rate without PMA is shown in Figure 9. Figure 9 shows that when the cells were incubated in 2 μ M PMA before membrane potential measurements, the repolarization rate in affected cells was significantly different from the repolarization rate in unaffected cells by t-test ($P = 0.029$).

Figure 10 shows the effect of PMA on the relative ratio of repolarization rates. The rate of drop in membrane potential (repolarization rate) in affected cells incubated for 30 minutes in both K^+ -free buffer and in K^+ -containing (regular) buffer in the presence or absence of 2 μ M PMA was compared to that of unaffected cells incubated for 30 minutes in both K^+ -free buffer and in K^+ -containing buffer in the presence or absence of 2 μ M PMA. The difference in the median values between the two groups was greater than would be expected by chance. As shown in Figure 10, the relative ratio of repolarization rates was significantly lower in affected cells compared to that in unaffected cells ($P = 0.046$, as determined by t-test).

Example 7

Lithium-Induced Changes In Membrane Potential

The effect of the addition of lithium, a clinically proven mood stabilizer, on changes in membrane potential in K^+ -free buffer and in K^+ -containing buffer was measured. Cells were incubated with or without lithium chloride (LiCl 20 mM) for 2 hours in K^+ -free buffer or in K^+ -containing buffer.

A constant sample volume of each cell line was added to an equal volume of each buffer containing an equal volume of dye. Thus, the K^+ -free buffer and the K^+ -containing buffer contained an equal number of
5 cells from each culture sample and an equal concentration of dye.

The membrane potential of these cells was determined by measuring the fluorescence intensity as described above. The intensity ratio (membrane
10 potential with lithium/membrane potential without lithium) was compared to the intensity ratio in K^+ -containing buffer and/or in K^+ -free buffer. The relative intensity ratio was obtained by dividing the intensity ratio in K^+ -free buffer by the
15 intensity ratio in K^+ -containing buffer. As shown in Figure 11, the relative intensity ratio (ratio in K^+ -free buffer with and without lithium/ratio in K^+ -containing (regular) buffer with and without lithium) of affected cells was significantly higher
20 than that of unaffected cells by t-test ($P = 0.04$).

Example 8

Open Clinical Trials

A pilot clinical trial was conducted using
25 blood samples from 12 clinically affected bipolar patients and 11 unaffected controls. The medical histories of the patients were known to the investigator measuring the membrane potentials; therefore, the trials described in this example were
30 open trials. The patients ranged from 19 years to 77 years in age, and included males and females from different ethnic groups. Similarly, the controls ranged from 25 to 67 including males and females

from different ethnic groups. The patients were all hospitalized following a confirmed manic episode. During the drawing of samples, all patients were on mood stabilizers, either lithium or valproate.

5 Because the volume of blood required to collect enough lymphocytes was beyond that permitted by the current protocol, the membrane potential of whole blood cells was determined. The volume of whole blood required was approximately 1 ml. The blood
10 samples were kept on ice until they were stored at 4°C. All of the samples were tested within 48 hours.

 Whole blood samples drawn from patients and controls were suspended in K⁺-containing buffer without ethacrynate and in K⁺-free buffer with 30μM
15 ethacrynate or with 100 mM sorbitol. The fluorescent dye DiOC₆(3) was added to both suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The
20 fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated.

 Tables 5 and 6 below present the statistical analysis of the data generated in the trials.

25

TABLE 5

Clinical Trials (Open Samples)

Normality Test: Passed (P > 0.050)

5 Equal Variance Test: Passed (P = 0.523)

Group Name	N	Missing	Mean	Std Dev	SEM
Controls	98	0	0.893	0.0485	0.00489
Bipolars	109	0	0.780	0.0521	0.00499

10 Difference 0.114

t = 16.204 with 205 degrees of freedom. (P = <0.001)

15 95 percent confidence interval for difference of means: 0.0999 to 0.128

The difference in the mean values of the two groups is greater than would be expected by chance; there is a statistically significant difference between the input groups (P = <0.001).

20

Power of performed test with alpha = 0.050: 1.000

TABLE 6

25

Descriptive Statistics:

Column	Size	Missing	Mean	Std Dev	Std. Error	C.I. of Mean
30 Controls	98	0	0.893	0.0485	0.00489	0.00971
Bipolars	109	0	0.780	0.0521	0.00499	0.00990

Column	Range	Max	Min	Median	25%	75%
35 Controls	0.256	1.053	0.797	0.893	0.860	0.925
Bipolars	0.250	0.880	0.629	0.778	0.751	0.817

Column	Skewness	Kurtosis	K-S Dist.	K-S Prob.	Sum	Sum of Squares
40 Controls	0.287	0.141	0.0418	0.863	87.558	78.457
Bipolars	-0.425	0.0710	0.0693	0.219	84.988	66.559

Table 5 above indicates that these data passed both the normality test and equal variance test.

45 Table 6 above shows that the mean value is very close to the median value for each of these groups, indicating that the data are normally distributed. The t-test shows significant variance (P << 0.001) among the two groups in open trials, with post-hoc

50 comparisons showing significant differences between controls and bipolar patients.

Figure 12 graphically depicts the data presented in Tables 5 and 6 above, showing the ratio of fluorescence intensities of the control and bipolar groups in K^+ -free buffer containing 30 μM ethacrynate to the fluorescence intensity in K^+ -containing buffer without ethacrynate. The mean fluorescence intensity ratio of the bipolar samples was significantly lower than that of the control samples by t-test.

Figure 13 shows that with bipolar patients the results with sorbitol were comparable to the results with ethacrynate. This figure shows a comparison of fluorescence intensity ratios of bipolar cells using ethacrynate and sorbitol in K^+ -free buffer.

Example 9

Blind Clinical Trials

A clinical trial was conducted using blood samples from the following four groups: schizophrenic, bipolar, and unipolar patients, as well as controls. The medical histories of these patients were unknown to the investigator measuring the membrane potentials; therefore, the trials described in this example were blind trials. The sample size was determined to be 5 with a power of 0.9, an alpha of 0.05, a difference in mean of 0.08, and a standard deviation of 0.03. However, more than 10 samples for each category were tested for a total sample size of 59. If a patient matched a diagnosis, structured clinical interviews according to DSM-IV guidelines were performed.

Whole blood samples drawn from patients and controls were suspended both in K^+ -containing buffer

and in K⁺-free buffer with 30μM ethacrynate or with 100 μM sorbitol. The fluorescent dye DiOC₆(3) was added to both suspensions and incubated for 30 minutes. The cell suspensions loaded with the dye were centrifuged, drained and resuspended in the respective buffers. The fluorescence intensity was measured for 10 seconds and the ratio of the intensity in K⁺-free buffer to the intensity in K⁺-containing buffer was calculated.

Tables 7 and 8 below present the statistical analysis of the four groups.

TABLE 7

One Way Analysis of Variance SUMMARY OF BLIND TRIALS

Normality Test: Passed (P > 0.050)
 Equal Variance Test: Failed (P = <0.001)

Test execution ended by user request, ANOVA on Ranks begun

Kruskal-Wallis One Way Analysis of Variance on Ranks

	Group	N	Missing	Median	25%	75%
25	Controls	173	0	0.850	0.829	0.869
	Schizophr.	78	0	0.863	0.838	0.895
	Bipolars	178	0	0.773	0.752	0.790
	Unipolars	72	0	0.901	0.863	0.934

H = 351.025 with 3 degrees of freedom. (P = <0.001)

The differences in the median values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001)

To isolate the group or groups that differ from the others use a multiple comparison procedure.

All Pairwise Multiple Comparison Procedures (Dunn's Method):

	Comparison	Diff of Ranks	Q	P<0.05
40	Unipolars vs Bipolars	308.546	15.260	Yes
	Unipolars vs Controls	95.297	4.694	Yes
	Unipolars vs Schizophr.	52.263	2.209	No
45	Schizophr. vs Bipolars	256.283	13.037	Yes
	Schizophr. vs Controls	43.034	2.180	No
	Controls vs Bipolars	213.249	13.797	Yes

TABLE 8**Descriptive Statistics: SUMMARY OF BLIND TESTS**

5	Column	Size	Missing	Mean	Std Dev	Std. Error	C.I. of Mean
	Controls	173	0	0.850	0.0290	0.00220	0.00435
	Schizophr.	78	0	0.870	0.0428	0.00484	0.00964
	Bipolars	178	0	0.768	0.0300	0.00225	0.00444
	Unipolars	72	0	0.898	0.0486	0.00573	0.0114
10	Column	Range	Max	Min	Median	25%	75%
	Controls	0.180	0.929	0.749	0.850	0.829	0.869
	Schizophr.	0.200	0.994	0.794	0.863	0.838	0.895
	Bipolars	0.164	0.830	0.667	0.773	0.752	0.790
15	Unipolars	0.199	1.004	0.805	0.901	0.863	0.934
	Column	Skewness	Kurtosis	K-S Dist.	K-S Prob.	Sum	Sum of Squares
	Controls	0.0895	0.607	0.0400	0.661	147.073	125.176
20	Schizophr.	0.682	0.132	0.0827	0.203	67.885	59.222
	Bipolars	-0.601	0.187	0.0742	0.018	136.709	105.156
	Unipolars	0.0506	-0.849	0.0762	0.362	64.645	58.210

Figure 14 graphically depicts the data presented in Tables 7 and 8 above, showing a summary of these blind test results using whole blood samples. The figure shows the ratio of fluorescence intensities of the sample groups in K⁺-free buffer containing 30 μ M ethacrynate to the fluorescence intensity in K⁺-containing buffer without ethacrynate. The coefficient of variation ranged from 3.5 to 4.5 in all these tests. There were no significant differences among the normals and schizophrenics. However, blood samples from bipolar patients were significantly different from the other three groups, as determined by ANOVA (P << 0.001). In particular, the fluorescence intensity ratio of the bipolar samples was significantly lower than that of the other three groups. Furthermore, there was a significant difference between normals and unipolar patients, as determined by ANOVA. In particular, the fluorescence intensity ratio of the unipolar samples was significantly higher than that

of the other three groups. These results are therefore useful in diagnosing unipolar (depressive) patients as well.

5

Example 10

Diagnosis of an Individual Patient as Bipolar

An individual patient's cell sample was tested as described herein and six to twelve ratios were calculated. These values were treated as a group and
10 compared with a normal control group (negative control) and a bipolar group (positive control).

Tables 9 and 10 below present the statistics and the procedure employed for "Patient A." At the bottom of Table 9 there is pair wise comparison of
15 these groups.

TABLE 9

One Way Analysis of Variance

Normality Test: Passed (P > 0.050)

5 Equal Variance Test: Passed (P = 0.050)

Group Name	N	Missing	Mean	Std Dev	SEM
Controls	173	0	0.850	0.0290	0.00220
Bipolars	178	0	0.768	0.0300	0.00225
10 Patient A	12	0	0.766	0.0125	0.00359

Source of Variation	DF	SS	MS	F	P
Between Groups	2	0.613	0.306	360.229	<0.001
Residual	360	0.306	0.000850		
15 Total	362	0.919			

The differences in the mean values among the treatment groups are greater than would be expected by chance; there is a statistically significant difference (P = <0.001).

20 Power of performed test with alpha = 0.050: 1.000

All Pairwise Multiple Comparison Procedures (Holm-Sidak method):

25 Overall significance level = 0.05

Comparisons for factor:

Comparison	Diff of Means	t	Unadjusted P	Critical Level	Significant?
Controls vs Bipolars	0.0821	26.372	0.000	0.017	Yes
Controls vs Patient A	0.0844	9.699	0.000	0.025	Yes
Bipolars vs Patient A	0.00233	0.268	0.789	0.050	No

30

TABLE 10

Descriptive Statistics:

Column	Size	Missing	Mean	Std Dev	Std. Error	C.I. of Mean
35 Controls	173	0	0.850	0.0290	0.00220	0.00435
Bipolars	178	0	0.768	0.0300	0.00225	0.00444
Patient A	12	0	0.766	0.0125	0.00359	0.00791

Column	Range	Max	Min	Median	25%	75%
40 Controls	0.180	0.929	0.749	0.850	0.829	0.869
Bipolars	0.164	0.830	0.667	0.773	0.752	0.790
Patient A	0.0394	0.787	0.748	0.763	0.755	0.777

Column	Skewness	Kurtosis	K-S Dist.	K-S Prob.	Sum	Sum of Squares
45 Controls	0.0895	0.607	0.0400	0.661	147.073	125.176
Bipolars	-0.601	0.187	0.0742	0.018	136.709	105.156
Patient A	0.347	-1.092	0.138	0.665	9.188	7.037

As shown in Tables 9 and 10 above, there was a significant difference between controls and the patient. However, there was no significant difference between the patient and the bipolar group. From this, Patient A was diagnosed as bipolar.

Figure 15 graphically depicts an example of the use of ANOVA in the diagnosis of Patient A as bipolar. The ratio of fluorescence intensities and therefore membrane potentials in K^+ -free buffer containing 30 μM ethacrynate was compared to the fluorescence intensity in K^+ -containing buffer without ethacrynate. The fluorescence intensity ratio of the patient's cell sample was significantly lower than that of the controls, but was not significantly different from that of the bipolars.

Example 11

Diagnosis of an Individual Patient as Unipolar

An individual patient's cell sample is tested as described herein and six to twelve ratios are calculated. These values are treated as a group and compared with a normal control group (negative control) and a unipolar group (positive control), in a manner similar to that described above in Example 10 for diagnosing an individual patient as bipolar.

The ratio of fluorescence intensities and therefore membrane potentials in K^+ -free buffer containing 30 μM ethacrynate are compared to the fluorescence intensity in K^+ -containing buffer without ethacrynate.

A patient is diagnosed as unipolar when there is a significant difference between controls and the

patient (i.e., the fluorescence intensity ratio of the patient's cell sample is significantly higher than that of the controls) and/or there is no significant difference between the unipolar group
 5 and the patient. ANOVA is used in the diagnosis of a patient as unipolar.

Example 12

Specificity and Sensitivity of the Diagnostic Whole

10 Blood Tests

Specificity is the ability to identify those who do not have the disease (Dawson et al, "Basic and Clinical Biostatistics", Third Edition, Lange Medical Books/McGraw-Hill, New York (2002)). As
 15 shown below in Table 11, the specificity in identifying controls was 100% in the blind trials described above in Example 9. Out of a control population (those with no known mental illness) of
 18, all were diagnosed as negative for a bipolar
 20 disorder. The specificity for the overall non-bipolar (including schizophrenics and unipolars) population of 39 was 85% (33 out of 39) in the above-described blind trials. Among the schizophrenic patients, the test diagnosed 8 out of
 25 10 correctly, indicating a specificity of 80% in the above-described blind trials. The specificity for the unipolar patients was 64% (seven out of eleven) in the above-described blind trials.

Sensitivity is defined as a test's ability to
 30 detect a disease among patients who actually have the disease (Dawson et al, *supra*). In the above-described blind trials, among the population of 20 bipolar patients (which were determined according to

examination using the DSM IV), 14 were true positives. Hence the sensitivity of the test was 70%. However, doubts about the accuracy of DSM IV-based diagnoses of a bipolar disorder make the estimate of sensitivity unclear.

Consideration was given to whether patients on lithium and patients with diabetes during the blood draw could generate false diagnoses. Of the true positives, one patient was on lithium and 2 were diabetic. Of the false negatives, 2 patients were on lithium and 4 were diabetic. Lithium and diabetes did not have an effect on false positives and true negatives. Thus, lithium and diabetes did not appear to play a role on these tests.

TABLE 11

Summary Of Blind Tests For Bipolar Disorder

Total samples tested:	59
Total positives:	20
Total negatives:	39

Diagnostic Blind Test Results

Total negatives	39
True negatives	33
Specificity	85%
Total controls	18
True controls	18
Specificity	100%
Total schizophrenics	10
True schizophrenics	8
Specificity	80%
Total unipolars	11
True unipolars	7
Specificity	64%
Total bipolars	20
True positives	14
Sensitivity	70%

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be
5 made therein without departing from the spirit and scope thereof. All such obvious and foreseeable changes and modifications are intended to be encompassed by the following claims.